3SOF

I'm really surprised there's not a thread for this one. Nobody follows it? Not even you DNDN fans?

I bought a very small amount of this just before the close after the "bad" news came out. 300 shares @$4.95. (long red day) Tried to catch the falling knife gambling a little for a good bounce in the morning that didn't come. Oh well. I doubled up at 2.74 and then put it in the long term portfolio. Maybe look back in a few months with a pleasant surprise and if I lost most of it,  no big deal. I really hadn't paid it any attention again until just this evening. I'm only down like $40 on it now. Anyone have an opinion whether it's worth putting  more into? Like David, I don't usually fool with many biotechs, and I know VERY little about this one.

The chart seems to look bullish again? Or not? Up 16% today to $3.81.

http://stockcharts.com/h-sc/ui?s=IDMI&p=D&b=5&g=0&id=p04887559183

Profile: 
 

IDM Pharma, Inc.
9 Parker
Suite 100
Irvine, CA 92618
United States - Map
Phone: 949-470-4751
Web Site: http://www.idm-biotech.com

DETAILS   
Index Membership: N/A
Sector: Healthcare
Industry: Biotechnology
Full Time Employees: 81


BUSINESS SUMMARY:   
IDM Pharma, Inc., a biopharmaceutical company, engages in the development of products to treat and control cancer. The company primarily develops product candidates to destroy residual cancer cells, as well as product candidates to stimulate an immune response and prevent tumor recurrence. Its products include Junovan, an immune system stimulant, which completed phase III study for the treatment of osteosarcoma; Bexidem, a cell-based immunotherapeutic, which is in phase II trials for the treatment of bladder cancer; and Uvidem, which is in Phase II clinical trials for the treatment of melanoma, consists of dendritophages and melanoma tumor cell lysates. The company?s products also include EP-2101, which has multiple tumor-associated CTL epitopes, is in Phase II trials for the treatment of non-small cell lung cancer; and Collidem, which is in Phase I/II trails for the treatment of Colorectal cancer, consists of dendritophages and tumor associated antigen peptides. It operates in the United States and France. IDM Pharma has collaboration agreements with sanofi-aventis S.A; Medarex, Inc.; GenPharm International, Inc.; Novartis; and Biotecnol S.A. The company is based in Irvine, California.



Business Overview: 
BRIEF: For the fiscal year ended 31 December 2006, IDM Pharma Inc.'s revenues rose 32% to $11.3M. Net loss fell 40% to $23.5M. Revenues reflect higher related party revenue due to the increase in Uvidem expenses associated with Uvidem clinical trials. Lower loss reflects decreased selling & marketing expenses and the absence of $13.3M charge relating to acquired in process research & development expenses. http://www.idm-biotech.com/


Float (mil) 9.90.......Shares Outstanding (mil) 17.96

IRVINE, Calif., May 30, 2007 /PRNewswire-FirstCall via COMTEX/ -- IDM Pharma, Inc. (IDMI, Trade) today announced that data from a Phase II UVIDEM(R) melanoma vaccine clinical trial and data from the Phase II EP-2101 non-small cell lung cancer (NSCLC) vaccine clinical trial will be presented at the 2007 American Society of Clinical Oncology (ASCO) 43rd annual meeting in Chicago on June 1-5 2007.


    UVIDEM presentation details: 
    --  "Clinical and immunological responses in patients with malignant 
        melanoma treated with a dendritic cell-based vaccine. Preliminary 
        report from a multi-institutional phase II clinical trial." Abstract 
        # 3004, Session: Developmental Therapeutics: Immunotherapy. Oral 
        presentation by Merrick I. Ross, M.D., Professor of Surgery, Chief, 
        Melanoma Section, Department of Surgical Oncology at M. D. Anderson 
        Cancer Center. 
    --  June 5, 2007 at 7.45 AM 
    --  Location: E354a 
    EP-2101 presentation details: 
    --  "Phase II trial of a 10-epitope CTL vaccine, EP-2101, in metastatic 
        NSCLC patients." Abstract # 3068, Session: Developmental Therapeutics: 
        Immunotherapy. Poster presentation. 
    --  June 3, 2007, 8.00 AM - 12 PM 
    --  Location: S Hall A2 

About the UVIDEM(R) Clinical Trial

The U.S. clinical trial is designed to assess the safety and clinical activity of UVIDEM in patients with stage III or IV melanoma with measurable lesions. Participating centers include the University of California Los Angeles (UCLA) Jonsson Comprehensive Cancer Center, the MD Anderson Cancer Center, the University of Pittsburgh, the Arizona Cancer Center and Lutheran General Cancer Care Center

About the EP-2101 Clinical Trial

The U.S. clinical trial is designed to assess overall survival and vaccine safety, with vaccine immunogenicity as a secondary endpoint in HLA-A2+ patients with stage IIIb, IV or recurrent non-small cell lung cancer, or NSCLC. The trial design was an open label, non-placebo trial with one year follow-up for survival. Sixty-four patients were enrolled in the trial with the last patient enrolled in March 2006.

About UVIDEM(R)

UVIDEM is a therapeutic specific immunostimulant developed by IDM Pharma in partnership with sanofi-aventis. Sanofi-aventis has worldwide marketing rights to UVIDEM in melanoma. UVIDEM consists of mature dendritic cells loaded with lysates from melanoma tumor cell lines. UVIDEM is produced in IDM Pharma GMP manufacturing facilities in Irvine, California and in Paris, France. UVIDEM has been administered to 143 patients in clinical development. Completion of patient enrollment in two Phase II clinical trials was previously announced. Thirty-eight patients with malignant melanoma were included in the US Phase II study and 53 patients with resected stage II/III melanoma were included in the European randomized Phase II study.

About EP-2101

The EP-2101 cancer vaccine candidate used in this trial includes nine CTL epitopes from four tumor associated antigens (TAA) including two proprietary native epitopes and seven modified, or analog, epitopes. Tolerance to TAA, which is a failure of the immune system to recognize the cancer as diseased tissue, is broken by using these analog epitopes which enhance the potency of the T cell response. PADRE(R), a universal HTL epitope we have licensed from Pharmexa, is also included in the vaccine as an immunostimulant. The phase II EP-2101 study has been ongoing since late 2004.

About Melanoma

According to the American Cancer Society, in 2007 approximately 59,940 new cases are expected to be diagnosed and it is estimated that approximately 8,110 people in the United Sates will die from the disease.

About Lung Cancer

Cancer of the lungs continues to be a major health problem with a very high mortality rate and represents the leading cause of cancer death in the United States. According to the American Cancer Society, approximately 213,380 new lung cancer cases will be diagnosed in the United States in 2007, and an estimated 160,390 patients will die from lung cancer. The American Cancer Society also estimates that non-small cell lung cancer, or NSCLC, represents 87% of all lung cancers.

About IDM Pharma

IDM Pharma (IDM) is a biopharmaceutical company focused on the development of innovative products that activate the immune system to treat cancer. IDM's lead product candidate, JUNOVAN(TM) (mifamurtide for injection), known as MEPACT in Europe, is part of a new family of immunotherapeutic agents designed to destroy residual cancer cells by activating the body's natural defenses. IDM's applications requesting marketing approval of JUNOVAN for use in the treatment of newly diagnosed resectable high-grade osteosarcoma patients in combination with multiple agent chemotherapy are in review by the U.S. Food and Drug Administration, or FDA, in the United States and by the European Medicines Agency, or EMEA, in Europe. IDM is jointly developing UVIDEM, a cell-based vaccine product candidate in Phase II clinical trials for the treatment of melanoma, with sanofi-aventis. EP-2101 is currently being tested in non-small cell lung cancer (NSCLC) patients in a Phase II clinical trial and is composed of multiple tumor-specific CTL epitopes selected from tumor-associated antigens

For more information, visit http://www.idm-pharma.com.

About sanofi-aventis

Sanofi-aventis is one of the world leaders in the pharmaceutical industry, ranking number one in Europe. Backed by a world-class R&D organization, sanofi-aventis is developing leading positions in seven major therapeutic areas: cardiovascular, thrombosis, oncology, metabolic diseases, central nervous system, internal medicine and vaccines. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (SNY, Trade).

Forward-Looking Statements

This press release includes and the presentation described in this press release will include forward-looking statements that reflect management's current views of future events including statements regarding the phase II UVIDEM study and the potential for UVIDEM as a treatment for melanoma and the phase II EP-2101 study and the potential for EP-2101 as a treatment for NSCLC, and review of the submissions for marketing approval of JUNOVAN by the FDA and the EMEA. Actual results may differ materially from the forward-looking statements due to a number of important factors, including, but not limited to, the timing of the FDA's and EMEA's review of the submissions for marketing approval, the ability of the Company to respond to questions raised by the FDA and EMEA in a satisfactory manner, the time needed to respond to any issues raised by the FDA and EMEA with regard to regulatory submissions for JUNOVAN, although the FDA is not bound by the decision of any advisory panel, the possible negative impact that the opinion of the FDA's Oncologic Drug Advisory Committee that the results of the Company's Phase III trial do not provide substantial evidence of effectiveness of JUNOVAN in the treatment of patients with non-metastatic, resectable osteosarcoma receiving combination chemotherapy would have upon the determination by the FDA whether to approve the marketing application for JUNOVAN, which would have a material and adverse affect on IDM's business, the possibility that regulatory authorities may not consider preclinical and early clinical development work conducted by Ciba-Geigy and efficacy data from the Phase III trial conducted by Children's Oncology Group as adequate for their assessment of JUNOVAN, which may cause delays in review, may result in the regulatory authorities requiring the Company to conduct additional clinical trials, or may result in a determination by the regulatory authorities that the data does not support marketing approval, whether regulatory authorities will approve JUNOVAN within the time frame expected by the Company or at all, and whether the Company will be able to manufacture JUNOVAN even if it is approved by regulatory authorities. Other risks affecting the Company and its drug development programs include whether the Company or any of its collaborators will be able to develop pharmaceutical products using the technologies of the Company, whether clinical trial results to date are predictive of results of any future clinical trials, risks associated with completing clinical trials of product candidates, risks involved in the regulatory approval process for the Company's product candidates, the possibility that clinical testing may reveal undesirable and unintended side effects or other characteristics that may prevent or limit the commercial use of proposed products; whether the cash resources of the Company will be sufficient to fund operations as planned; whether any steps taken by the Company to contain costs will in fact result in sufficient reduction in expenses; reliance on key employees, especially senior management; the risk that the Company may not secure or maintain relationships with collaborators, and the Company's dependence on intellectual property. These factors are more fully discussed in the Company's Annual Report on Form 10-K filed with the SEC for the year ended December 31, 2006 and other periodic reports filed with the SEC. The Company expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.


    CONTACT: 
    Bob De Vaere 
    IDM Pharma, Inc. 
    Chief Financial Officer 
    Office: 949-470-6447 

SOURCE IDM Pharma, Inc.


Bob De Vaere, Chief Financial Officer of IDM Pharma, Inc., +1-949-470-6447 

http://www.idm-pharma.com 

Copyright (C) 2007 PR Newswire. All rights reserved ********************************************************************** As of Saturday, 05-26-2007 23:59, the latest Comtex SmarTrend? Alert, an automated pattern recognition system, indicated an UPTREND on 04-05-2007 for SNY @ $43.90. For more information on SmarTrend, contact your market data provider or go to www.mysmartrend.com SmarTrend is a registered trademark of Comtex News Network, Inc. Copyright ? 2004-2007 Comtex News Network, Inc. All rights reserved.

Thought I would help your thread out and put some Info in,hope you don't mind.
After reading through their stuff......this looks like a great company.
Closed Friday above the 200-day MA.

Biggest % Gainers: After a Cantor Fitzgerald analyst predicted IDM Pharma (IDMI) would quadruple over the next year. Analysts expect the company's bone cancer drug, Junovan, to be in high demand when it is approved and launched by the end of the year.

Support @ $3.76...2.92...2.34
Resistance @ $5.05...5.92...6.66

52wk Range: 2.22 - 10.75
Volume: 1,862,062
Avg Vol (3m): 604,980

Technicals
Percentage Gainer

Last Price Quote is:
13.81%above 13-day MA
-11.04%below 50-day MA
RS Rating: 84 

Fundamentals
Key Data:
Market Cap (M): $68.42 
P/E Ratio: N/A 
PEG Ratio: N/A 
Next Earnings: 08/13/2007
Last Analyst Rating: Buy


Insider Transactions Link : http://finance.yahoo.com/q/it?s=IDMI
Major Holders Link : http://finance.yahoo.com/q/mh?s=IDMI
Insider Roster Link : http://finance.yahoo.com/q/ir?s=IDMI

Quote from: setravis on June 02, 2007, 05:15:49 PM
Thought I would help your thread out and put some Info in,hope you don't mind.
After reading through their stuff......this looks like a great company.
Closed Friday above the 200-day MA.

Of course I didn't mind, Setravis. It's just the Kind of input I was looking and hoping  for as these Bios are very hard for me to evaluate myself. Thanks much and applause.

IDMI filled both gaps now. Will it continue higher?

http://stockcharts.com/h-sc/ui?s=IDMI&p=D&b=5&g=0&id=p04887559183

IDMI had a nice end of day breakout on the 5 min chart to rally back near the high of day - with decent volume.  May be good sign for tomorrow.  But with biotechs you never know!!   

Jason

Is IDMI going to breakout on the 5 min chart again to the upside like yesterday??  We shall see.  You never know with bios!!   

Happy Trading!
Jason

nice rally today!

http://stockcharts.com/h-sc/ui?s=IDMI&p=D&b=5&g=0&id=p04887559183

friday nice move up, we can see eu aprovall on 13dec

up 40%

volume picked up. I still have shares of this bio dog, but don't really know or care whats going on with it. Bios not really my thing.

trading at $1.46 now

up 62% now.

Very nice.

Never bought though